|
1
|
New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists.
|
Life Sci
|
2005
|
1.02
|
|
2
|
Anxiolytic-like effects of N,N-dialkyl-2-phenylindol-3-ylglyoxylamides by modulation of translocator protein promoting neurosteroid biosynthesis.
|
J Med Chem
|
2008
|
0.93
|
|
3
|
Perinatal asphyxia: current status and approaches towards neuroprotective strategies, with focus on sentinel proteins.
|
Neurotox Res
|
2010
|
0.87
|
|
4
|
A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
|
Neuropharmacology
|
2009
|
0.85
|
|
5
|
Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
|
Synapse
|
2008
|
0.83
|
|
6
|
Strain dependence of adolescent Cannabis influence on heroin reward and mesolimbic dopamine transmission in adult Lewis and Fischer 344 rats.
|
Addict Biol
|
2013
|
0.82
|
|
7
|
Performance of movement in hemiparkinsonian rats influences the modifications induced by dopamine agonists in striatal efferent dynorphinergic neurons.
|
Exp Neurol
|
2013
|
0.82
|
|
8
|
Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease.
|
Neurotox Res
|
2009
|
0.82
|
|
9
|
Nicotinamide prevents the long-term effects of perinatal asphyxia on apoptosis, non-spatial working memory and anxiety in rats.
|
Exp Brain Res
|
2009
|
0.81
|
|
10
|
Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats.
|
Eur J Pharmacol
|
2007
|
0.81
|
|
11
|
Dyskinesia in Parkinson's disease: mechanisms and current non-pharmacological interventions.
|
J Neurochem
|
2014
|
0.81
|
|
12
|
Potentiation of amphetamine-mediated responses in caffeine-sensitized rats involves modifications in A2A receptors and zif-268 mRNAs in striatal neurons.
|
J Neurochem
|
2006
|
0.80
|
|
13
|
Anxiolytic properties of a 2-phenylindolglyoxylamide TSPO ligand: Stimulation of in vitro neurosteroid production affecting GABAA receptor activity.
|
Psychoneuroendocrinology
|
2010
|
0.80
|
|
14
|
Alteration in the progression of dopamine neuron degeneration: may caffeine offer new perspective?
|
Exp Neurol
|
2012
|
0.78
|
|
15
|
Methylxanthines and drug dependence: a focus on interactions with substances of abuse.
|
Handb Exp Pharmacol
|
2011
|
0.78
|
|
16
|
Elevation of striatal urate in experimental models of Parkinson's disease: a compensatory mechanism triggered by dopaminergic nigrostriatal degeneration?
|
J Neurochem
|
2014
|
0.76
|
|
17
|
Microglial and astroglial activation by 3,4-methylenedioxymethamphetamine (MDMA) in mice depends on S(+) enantiomer and is associated with an increase in body temperature and motility.
|
J Neurochem
|
2012
|
0.76
|
|
18
|
MDMA administration during adolescence exacerbates MPTP-induced cognitive impairment and neuroinflammation in the hippocampus and prefrontal cortex.
|
Psychopharmacology (Berl)
|
2014
|
0.76
|
|
19
|
Can dietary substances protect against Parkinson's disease? The case of caffeine.
|
Exp Neurol
|
2010
|
0.75
|
|
20
|
A(2A) Receptor Antagonism and Dyskinesia in Parkinson's Disease.
|
Parkinsons Dis
|
2012
|
0.75
|
|
21
|
Erratum to: MDMA administration during adolescence exacerbates MPTP-induced cognitive impairment and neuroinflammation in the hippocampus and prefrontal cortex.
|
Psychopharmacology (Berl)
|
2015
|
0.75
|